Top Pharma News - IgeaHub

Top Pharma News of the Week

FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis Aug. 07, 2017 FibroGen, Inc., a science-based biopharmaceutical company, has announced positive topline results from the company’s Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). Pamrevlumab is a proprietary, … Continue reading Top Pharma News of the Week

Top 10 Oncology Pharmaceutical Companies 2017

Top 10 Oncology Pharmaceutical Companies 2017

The market for oncology medication is booming, aiding the overall pharmaceutical industry growth. The oncology drug market is estimated to be almost USD 94 billion. Most of the top pharmaceutical players are either currently manufacturing oncology drugs or have oncology medications in their R&D pipelines. An analysis of the top pharmaceutical companies was conducted to … Continue reading Top 10 Oncology Pharmaceutical Companies 2017

Top 20 Drugs in the World 2017

Top 20 Drugs in the World 2017

The global prescription drug market is expected to grow by 6% from 2016 to 2022 to reach nearly USD 1.05 trillion by 2022. The top 20 drugs are manufactured by 14 companies and account for a total 10% of global prescription drug market in 2016. The total revenue generated by top 20 products was estimated … Continue reading Top 20 Drugs in the World 2017

Top Pharma News - IgeaHub

Top Pharma News of the Week

Amgen Submits Supplemental Biologics License Application for Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis  July 31, 2017 Amgen has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The sBLA is based on a Phase 3 study evaluating the … Continue reading Top Pharma News of the Week

Top Pharma News - IgeaHub

Top Pharma News | July – August 2017

Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint July 5, 2017 Bristol-Myers Squibb Company has announced that a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection met its … Continue reading Top Pharma News | July – August 2017

Cancer Medication Market – A blockbuster area for investment

Cancer is one of the leading causes of morbidity and mortality worldwide, but therapeutic innovation has changed the treatment paradigm drastically. Cancer medication demand is increasing due to high unmet medical need and incidence rate. This reflects in growing revenues for pharmaceutical companies operating in this space and increasing investments in oncology R&D. The key … Continue reading Cancer Medication Market – A blockbuster area for investment

Top Pharma News - IgeaHub

Top Pharma News of the Week

Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint July 5, 2017 Bristol-Myers Squibb Company has announced that a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection met its … Continue reading Top Pharma News of the Week

Top Pharma News - IgeaHub

Top Pharma News | May – June 2017

AstraZeneca’s Imfinzi (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer 01 May 2017 AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab). Imfinzi is indicated for the treatment of patients with locally advanced or metastatic … Continue reading Top Pharma News | May – June 2017

Bristol-Myers Squibb Collaborates with Foundation Medicine to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents

March 30, 2017 Bristol-Myers Squibb Company and Foundation Medicine has announced a collaboration that leverages comprehensive genomic profiling and molecular information solutions of Foundation Medicine to identify predictive biomarkers like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in patients enrolled across clinical trials investigating cancer immunotherapies of Bristol-Myers Squibb. Biomarkers can be used to characterize a … Continue reading Bristol-Myers Squibb Collaborates with Foundation Medicine to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents

Top Pharma News - IgeaHub

Top Pharma News | March – April 2017

Bristol-Myers Squibb Planning Collaboration with GRAIL on Blood-Based Cancer Screening March 1, 2017 Bristol-Myers Squibb Company plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is to detect cancer early when it potentially can be cured. GRAIL aims to develop highly sensitive blood tests that detect cancer in its early … Continue reading Top Pharma News | March – April 2017